Detection of Serum/Plasma MicroRNA Markers and Its Application in Patients with Mild Cognitive Impairment

Abstract

The invention belongs to the field of biotechnology and neurocognition, and relates to the detection of serum / plasma microRNA markers in patients with mild cognitive impairment and applications thereof, wherein the markers are any one or both of miR‑206 and miRNA‑132 In combination, the markers are applied to the diagnosis of mild cognitive impairment patients, and the markers are applied to the preparation of kits for the diagnosis of mild cognitive impairment patients, and the application adopts real-time fluorescent quantitative polymerase chain reaction (Real ‑time PCR) to detect the content of serum / plasma miR‑206 and / or miRNA‑132 of the subjects, and compare them with those with normal cognition to diagnose mild cognitive impairment. The miRNA markers screened in this invention are specific for cognitive impairment, and the diagnosis of mild cognitive impairment is simple and highly sensitive, and is suitable for large-scale screening.

Description

technical field [0001] The invention relates to the application of serum / plasma microRNA (miRNA, referred to as miRNA), in particular to the detection of serum / plasma microRNA markers in patients with mild cognitive impairment and the application thereof, belonging to the technical fields of biotechnology and neurocognitive technology. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease that seriously threatens human health. Mild cognitive impairment (MCI) is a transitional state between Alzheimer's disease and normal aging. Studies have shown that 23% of patients with mild cognitive impairment will progress to Alzheimer's disease within 2 years, and 50% of patients will develop Alzheimer's disease within 4 years. Therefore, mild cognitive impairment is considered to be the most appropriate early intervention treatment for Alzheimer's disease stage. With the aging of the global population, the prevalence of mild cognitive impairment has in...

AI Technical Summary

Problems solved by technology

Although some cerebrospinal fluid markers (such as Aβ1-42, T-tau, P-tau, etc.) have been found (Alexopoulos et al., 2013), due to the traumatic nature of cerebrospinal fluid sample collection, clinical application must be strictly Master its indications and contraindications. In addition, the sensitivity and specificity of cerebrospinal fluid examination for the diagnosis of mild cognitive impairment are limited

Images